Search Results - "Youle, Michael"

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials by Eron, Joseph J, Prof, Young, Benjamin, MD, Cooper, David A, Prof, Youle, Michael, MD, DeJesus, Edwin, MD, Andrade-Villanueva, Jaime, MD, Workman, Cassy, MD, Zajdenverg, Roberto, MD, Fätkenheuer, Gerd, Prof, Berger, Daniel S, MD, Kumar, Princy N, MD, Rodgers, Anthony J, MS, Shaughnessy, Melissa A, MS, Walker, Monica L, BS, Barnard, Richard JO, PhD, Miller, Michael D, PhD, DiNubile, Mark J, MD, Nguyen, Bach-Yen, MD, Leavitt, Randi, MD, Xu, Xia, PhD, Sklar, Peter, Dr

“…Summary Background To reduce lipid abnormalities and other side-effects associated with antiretroviral regimens containing lopinavir-ritonavir, patients might…”
Get full text

Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection by Booth, Clare L., Garcia-Diaz, Ana M., Youle, Michael S., Johnson, Margaret A., Phillips, Andrew, Geretti, Anna Maria

“…Objectives To determine prevalence and predictors of antiretroviral drug resistance in newly diagnosed individuals with HIV-1 infection, using a systematic…”
Get full text

Human Immunodeficiency Virus Rebound after Suppression to <400 Copies/mL during Initial Highly Active Antiretroviral Therapy Regimens, according to Prior Nucleoside Experience and Duration of Suppression by Phillips, Andrew N., Staszewski, Schlomo, Lampe, Fiona, Youle, Michael S., Klauke, Stephan, Bickel, Markus, Sabin, Caroline A., Doerr, Hans Wilhelm, Johnson, Margaret A., Loveday, Clive, Miller, Veronica

“…This study evaluated 1433 human immunodeficiency virus (HIV)–infected patients starting highly active antiretroviral therapy (HAART), 409 (28%) of whom had…”
Get full text

Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives? by Horne, Robert, Kovacs, Colin, Katlama, Christine, Clotet, Bonaventura, Fumaz, Carmina R, Youle, Michael, Kulasegaram, Ranjababu, Fisher, Martin, Cohen, Calvin, Slim, Jihad, Shalit, Peter, Cooper, Vanessa, Tsoukas, Christos

“…The selection of agents for any treatment regimen is in part influenced by physician and patient attitudes. This study investigated attitudinal motivators and…”
Get full text

Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study by Mitchell, Suzanne M, Membrey, William L, Youle, Michael S, Obi, Adanna, Worrell, Simon, Gazzard, Brian G

“…BACKGROUND/AIMS There have been several recent reports suggesting that the natural history of cytomegalovirus retinitis (CMVR) has been significantly modified…”
Get full text

Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection by PHILLIPS, Andrew N, YOULE, Michael S, LAMPE, Fiona, JOHNSON, Margaret, SABIN, Caroline A, LEPRI, Alessandro Cozzi, LOVEDAY, Clive

“…Subpopulations of HIV with mutations associated with resistance to antiretroviral drugs often have reduced replicative capacity, so virus with resistance…”
Get full text

Selected topics from the XI International HIV Drug Resistance Workshop, Seville, and the XIV International AIDS Conference, Barcelona

Get more information

Pharmacokinetics and Absolute Bioavailability of Oral Foscarnet in Human Immunodeficiency Virus-Seropositive Patients by NOORMOHAMED, F. H, YOULE, M. S, HIGGS, C. J, MARTIN-MUNLEY, S, GAZZARD, B. G, LANT, A. F

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals by SCHIPANI, Alessandro, WYEN, Christoph, ROCKSTROH, Jürgen, BROCKMEYER, Norbert H, JOHNSON, Margaret A, OWEN, Andrew, BACK, David J, MAHUNGU, Tabitha, HENDRA, Heidy, EGAN, Deirdre, SICCARDI, Marco, DAVIES, Gerry, KHOO, Save, FÄTKENHEUER, Gerd, YOULE, Michael

“…Nevirapine is metabolized by CYP2B6 and polymorphisms within the CYP2B6 gene partly explain inter-patient variability in pharmacokinetics. The aim of this…”
Get full text

Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles by Touizer, Emma, Alrubayyi, Aljawharah, Ford, Rosemarie, Hussain, Noshin, Gerber, Pehuén Pereyra, Shum, Hiu-Long, Rees-Spear, Chloe, Muir, Luke, Gea-Mallorquí, Ester, Kopycinski, Jakub, Jankovic, Dylan, Jeffery-Smith, Anna, Pinder, Christopher L., Fox, Thomas A., Williams, Ian, Mullender, Claire, Maan, Irfaan, Waters, Laura, Johnson, Margaret, Madge, Sara, Youle, Michael, Barber, Tristan J., Burns, Fiona, Kinloch, Sabine, Rowland-Jones, Sarah, Gilson, Richard, Matheson, Nicholas J., Morris, Emma, Peppa, Dimitra, McCoy, Laura E.

“…We assessed a cohort of people living with human immunodeficiency virus (PLWH) (n = 110) and HIV negative controls (n = 64) after 1, 2 or 3 SARS-CoV-2 vaccine…”
Get full text

Feasibility of testing and detection of HIV-1 drug resistance in proviral DNA by Booth, Clare L, McCormick, Adele, Garcia-Diaz, Ana, Macartney, Malcolm, Youle, Michael, Johnson, Margaret, Webster, Daniel

Get full text

Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects by Noormohamed, F H, Youle, M S, Higgs, C J, Kook, K A, Hawkins, D A, Lant, A F, Thomas, S D

“…Thalidomide (alpha-N-phthalimidoglutarimide), a potent inhibitor of tumor necrosis factor alpha (TNF-alpha), is proving to be a promising drug in the treatment…”
Get more information

Reasons for modification and discontinuation of antiretrovirals : results from a single treatment centre by MOCROFT, Amanda, YOULE, Michael, JOHNSON, Margaret A, PHILLIPS, Andrew N, MOORE, Antonia, SABIN, Caroline A, MADGE, Sara, LEPRI, Alessandro Cozzi, TYRER, Mervyn, CHALONER, Clinton, WILSON, Debbie, LOVEDAY, Clive

“…To describe the reasons for, and factors associated with, modification and discontinuation of highly active antiretroviral therapy (HAART) regimens at a single…”
Get full text

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS : A randomized, controlled trial by LALEZARI, J. P, STAGG, R. J, KUPPERMANN, B. D, HOLLAND, G. N, KRAMER, F, IVES, D. V, YOULE, M, ROBINSON, M. R, DREW, W. L, JAFFE, H. S

“…Cytomegalovirus (CMV) retinitis is the most common intraocular infection in patients with the acquired immunodeficiency syndrome (AIDS). If left untreated, it…”
Get full text

A Step Ahead on the HIV Collaboratory by Murphy, Robert L., Katlama, Christine, Debre, Patrice, Clotet, Bonaventura, Costagliola, Dominique, Dorrell, Lucy, Gatell, Jose, Klein, Michel, McMichael, Andrew J., Schacker, Timothy W., Walker, Bruce D., Autran, Brigitte, Brucker, Gilles, Calvez, Vincent, Clumeck, Nathan, Deeks, Steven G., Haase, Ashley, Lazzarin, Adriano, Papagno, Laura, Wain-Hobson, Simon, Youle, Michael

Get full text

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population by MOCROFT, A, DEVEREUX, H, KINLOCH-DE-LOES, S, WILSON, D, MADGE, S, YOULE, M, TYRER, M, LOVEDAY, C, PHILLIPS, A. N, JOHNSON, M. A

“…Background: Highly active antiretroviral therapy (HAART) is now widely used in clinical practice and gives rise to a range of immunological, virological and…”
Get full text

Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development by PHILLIPS, Andrew N, YOULE, Michael, JOHNSON, Margaret, LOVEDAY, Clive

“…To use a stochastic model to gain insights into the consequence for resistance development of different drug use patterns. We consider use of three drugs (A, B…”
Get full text

A Randomized, Double-Blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection by Feinberg, Judith E., Hurwitz, Shelley, Cooper, David, Sattler, Fred R., MacGregor, Rob Roy, Powderly, William, Holland, Gary N., Griffiths, Paul D., Pollard, Richard B., Youle, Michael, Gill, M. John, Holland, Fiona J., Power, Maureen E., Owens, Susan, Coakley, Dion, Fry, John, Jacobson, Mark A.

“…Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine…”
Get full text

Clinical Efficacy of High-Dose Acyclovir in Patients with Human Immunodeficiency Virus Infection: A Meta-Analysis of Randomized Individual Patient Data by Ioannidis, John P. A., Collier, Ann C., Cooper, David A., Corey, Lawrence, Fiddian, A. Paul, Gazzard, Brian G., Griffiths, Paul D., Contopoulos-Ioannidis, Despina G., Lau, Joseph, Pavia, Andrew T., Saag, Michael S., Spruance, Spotswood L., Youle, Michael S.

“…A meta-analysis of 8 randomized trials (1792 patients, 2947 patient-years of follow-up) showed that acyclovir (⩾3200 mg/day) offered a significant survival…”
Get full text

Survival after diagnosis of AIDS : a prospective observational study of 2625 patients by MOCROFT, A, YOULE, M, MORCINEK, J, SABIN, C. A, GAZZARD, B, JOHNSON, M. A, PHILLIPS, A. N

“…OBJECTIVE: To estimate median survival and changes in survival in patients diagnosed as having AIDS. DESIGN: Prospective observational study. SETTING: Clinics…”
Get full text